Feed AZN
AZ

AstraZeneca

AZN · NYSE

$156.91 -0.50% (-$0.79)
1M -1.96%
Market Cap $243.2B
P/E Ratio 23.28x
Div. Yield 2.06%
ROE 21.75%

Bulios Fair Price

$194.69

24.1% upside

Trenutna cena

$156.91

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica AZN trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Strong
8/9
Valuation
54 /100
Fair
PEG 0.52x
P/E 23.28x
P/B 4.84x
Growth
82 /100
Growing
FCF growth 17.58%
EPS growth 45.80%
Book val. growth 9.53%
Profitability
92 /100
Strong
Op. margin 22.77%
Gross margin 81.88%
FCF margin 14.24%
Quality
76 /100
Excellent
ROA 9.03%
ROIC 12.83%
Asset turnover 0.53x
Debt
69 /100
Low
Int. coverage 8.26x
Debt/Equity 0.64x
Net debt/EBITDA 1.32x
Stability
46 /100
Moderate
EPS volatility 115.85%
Beta 0.21x
Profitable years 6

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o AZN
Online

O podjetju

AstraZeneca (AZN) is a British-Swedish pharmaceutical company specializing in the research, development, and production of drugs for a wide range of therapeutic areas, including oncology, cardiovascular, respiratory, and immunological diseases. The company is known for its emphasis on scientific innovation and global healthcare initiatives, enabling it to bring new treatment options to patients worldwide. AstraZeneca also invests in the development of biologics and personalized medicine to improve treatment efficacy and outcomes. AstraZeneca (AZN) shares could be suitable for investors looking for opportunities in the pharmaceutical sector with a focus on research, innovation, and a broad therapeutic portfolio.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Pascal Claude Roland Soriot

Employees

96,100

Headquarters

Cambridge

Prihajajoči dogodki

30 OKT.

Earnings

Upcoming earnings report

25d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.